Is It Too Late To Consider Masimo (MASI) After This Year’s 40% Rally?

• If you are wondering whether Masimo at around US$177.87 is offering value or asking you to pay up for quality, this breakdown will help you frame that question clearly.
• The stock has been relatively steady over the last week with a 0.5% decline, modestly higher over 30 days with a 1.4% gain, and much stronger year to date with a 39.6% return, compared with a 6.1% return over the past year and a 24.2% decline over five years.
• Recent headlines have focused on Masimo's position in medical technology and investor attention around its share price moves, which helps explain why the stock has attracted renewed interest this year. These news items give context to the stronger year to date return relative to the more mixed three and five year track record.
• Masimo currently records a valuation score of 1 out of 6. The next sections will compare what different valuation methods say about the stock and then finish with a broader way to think about value beyond any single model.

Masimo scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Masimo Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today at an appropriate rate. It is essentially asking what all of Masimo's future cash generation might be worth in present day dollars.

Masimo's latest twelve month free cash flow stands at about $172.7 million. Using a 2 Stage Free Cash Flow to Equity model, Simply Wall St starts with this base and then projects cash flows out to 2035. For example, free cash flow for 2026 is projected at $214.8 million, with a series of estimates reaching $412.4 million by 2035. Analysts typically provide detailed forecasts for only the first few years; later numbers in this path are extrapolated rather than direct analyst estimates.

When all of these projected cash flows are discounted back, the resulting intrinsic value is $128.66 per share. Compared with the recent share price of about $177.87, the DCF output suggests Masimo is around 38.2% overvalued on this model.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Masimo may be overvalued by 38.2%. Discover 58 high quality undervalued stocks or create your own screener to find better value opportunities.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Masimo.

Approach 2: Masimo Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. This makes it a useful cross check alongside a DCF model.

A higher or lower P/E often reflects what the market expects for future growth and how risky those earnings might be. Strong growth expectations or lower perceived risk can support a higher "normal" P/E, while slower growth or higher risk usually justifies a lower one.

Masimo currently trades on a P/E of 44.7x. That is above the Medical Equipment industry average of about 27.5x, and below the peer group average of 54.7x. Simply Wall St also provides a proprietary "Fair Ratio" for Masimo of 24.7x, which is the P/E level suggested after accounting for factors such as earnings growth characteristics, profit margins, industry, market cap and company specific risks.

This Fair Ratio aims to be more tailored than a simple comparison against peers or the broad industry, because it adjusts for the mix of growth, risk and profitability that is specific to Masimo.

Compared with the Fair Ratio of 24.7x, Masimo's current P/E of 44.7x points to the shares trading above this model-based reference level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Masimo Narrative

Earlier it was mentioned that there is an even better way to think about value. On Simply Wall St that starts with Narratives, where you set out your story for Masimo, link it to specific forecasts for revenue, earnings and margins, and let the platform on the Community page turn that story into a Fair Value that is compared with the current price. This Fair Value is then kept up to date as news or earnings arrive. One investor might build a Narrative that lines up with the analysts' US$178.60 fair value. Another investor, who is more cautious on risks like tariffs or hospital contract exposure, might set assumptions that point to a meaningfully lower figure and a very different view on whether Masimo looks attractively or fully priced to them today.

Do you think there's more to the story for Masimo? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com